[Hematopoietic growth factors (choice, chronology, combination].
Hematopoietic growth factors (HGF) or blood stem cell (BSC) transplantation can be used to decrease hematological toxicity due to high dose radio-chemotherapy. HGF can also be combined to BSC transplantation in different ways: administered either alone (during the steady state) or combined standard chemotherapy, HGF can increase BSC mobilisation and consequently the yield of BSC collected leading to a decrease of aplasia duration after transplantation; administered to the patient after transplant, they can decrease the period of granulocytopenia; HGF can also be used to expand ex vivo BSC before reinfusion to the patient. In these different situations, the best combination of HGF needs to be clarified.
Reiffers
J
J
Service d'hématologie, hôpital Haut Lévêque, CHU Bordeaux, Pessac, France.
D003131:Combined Modality Therapy; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D016879:Salvage Therapy; D014182:Transplantation, Autologous
D016178:Granulocyte-Macrophage Colony-Stimulating Factor
Les facteurs de croissance hématopoïétiques (choix, chronologie, combinaison).